Geode Capital Management’s Bone Biologics BBLG Stock Holding History

Geode Capital Management’s Portfolio BBLG Stock Details BBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,034	Closed	-$19.4K	–	4453
2025 Q1	$19.4K	Buy	4,034 +1,475	+58%	+$8.55K	﹤0.01%	4352
2024 Q4	$14.4K	Buy	+2,559	New	+$21K	﹤0.01%	4411
2023 Q4	–	Sell	-334	Closed	-$11.4K	–	4657
2023 Q3	$11.4K	Buy	+334	New	+$16.5K	﹤0.01%	4716

Other funds holding BBLG

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management's BBLG Position: Q2 2025 in Review

Geode Capital Management sold out of Bone Biologics (BBLG) in Q2 2025, closing a stake of 4,034 shares — an estimated $19.4K sold.

Geode Capital Management first reported a position in BBLG in Q3 2023 and held it in 3 quarters. The position peaked at $19.4K in Q1 2025. 4 funds tracked by Wall St. Rank hold BBLG as of Q2 2025.

Geode Capital Management reported no remaining Bone Biologics position as of Q2 2025 after selling out during the quarter.
Geode Capital Management sold 4,034 Bone Biologics shares in Q2 2025, an estimated $19.4K.
Geode Capital Management first reported a position in Bone Biologics in Q3 2023 and held it in 3 quarters.
Geode Capital Management's Bone Biologics position peaked at $19.4K in Q1 2025.
4 funds tracked by Wall St. Rank held Bone Biologics as of Q2 2025.

Based on Geode Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.